Studies have reported that IGF2-AS is a biomarker for cancer diagnosis and prognosis, including as a tumor suppressor in breast cancer [6], a promotor of glycolysis and apoptosis of gastric cancer cells via targeting miR-195/CREB1 axis [7], a potential target for colorectal cancer (CRC) treatment [8], as well as the prognosis and metastasis of gastric adenocarcinoma via serving as a ceRNA of miR-503 to regulate SHOX2 9. This evidence concerns the gene SHOX2 and gastric adenocarcinoma.